Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea

• Päätekijät: Byung Soo Kim (Tekijä), Dong Hyun Kim (Tekijä), Bong Seok Shin (Tekijä), Eun-So Lee (Tekijä), Seong Jin Jo (Tekijä), Chul Hwan Bang (Tekijä), Yeojun Yun (Tekijä), Yong Beom Choe (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: SAGE Publishing, 2024-02-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background: Secukinumab, a fully human monoclonal antibody, was approved in Korea for the treatment of moderate to severe psoriasis in September 2015. Objectives: To assess the safety and effectiveness of secukinumab in patients with moderate to severe psoriasis in Korea. Design: Multicenter, real-w...